RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Fusion Pharm Stock

Fusion Pharm ROA 2024

Fusion Pharm ROA

0

Ticker

FSPM

ISIN

US36113H1005

WKN

A1H9CD

In 2024, Fusion Pharm's return on assets (ROA) was 0, a 0% increase from the 0 ROA in the previous year.

Fusion Pharm Aktienanalyse

What does Fusion Pharm do?

Fusion Pharm Inc is a well-known company in the agricultural industry that operates in various business sectors. It was founded in 2010 by Scott Dittman with the idea of improving agricultural efficiency through the use of innovative technologies. Fusion Pharm has gradually built different business areas focused on the development and marketing of products for optimizing agriculture. One of Fusion Pharm's core areas is the production of modular cultivation systems for plants that utilize cutting-edge technologies. These systems, called "PharmaCubes," are designed to provide optimal conditions for plants and achieve higher crop yields. They are particularly intended for use in urban spaces and other environments where traditional cultivation methods may not be feasible. The advantage of these systems lies in their scalability, and they are optimized for indoor use. Another important business area for Fusion Pharm is the production of fertilizers and other agricultural chemicals. These products are marketed under the brand name "Agritabs" and are aimed at promoting healthier plant growth and higher crop yields. The agricultural chemicals are made from natural raw materials, making them more environmentally friendly than many other products on the market. They are intended for use in various industries, including agriculture, gardening and landscaping, and the food industry. In addition to manufacturing and supplying cultivation systems, Fusion Pharm also operates in the production and distribution of natural fertilizers and other agricultural chemicals. The company has also undertaken a pilot project for closed-room fish farming and established itself in the aquaculture industry. In recent years, the company has pursued an aggressive acquisition strategy to expand into new business fields. One of these acquisitions was the takeover of the cloud-based software company "CannaCube," which has developed a management system for cannabis cultivation. Through the acquisition of CannaCube, Fusion Pharm has now positioned its portfolio for the growing cannabis industry. The company has made a name for itself in the agricultural industry by optimizing existing processes for sustainable and efficient plant development. With its innovative technology and products, the company contributes to greater efficiency and a more environmentally friendly agricultural industry. Fusion Pharm ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Fusion Pharm's Return on Assets (ROA)

Fusion Pharm's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Fusion Pharm's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Fusion Pharm's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Fusion Pharm’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Fusion Pharm stock

What is the Return on Assets (ROA) of Fusion Pharm this year?

The Return on Assets (ROA) of Fusion Pharm is 0 undefined this year.

What was the ROA of Fusion Pharm compared to the previous year?

The ROA of Fusion Pharm has increased by 0% compared to the previous year.

What consequences do high ROA have for investors of Fusion Pharm?

A high ROA is advantageous for investors of Fusion Pharm, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Fusion Pharm?

A low ROA can be unfavorable for investors of Fusion Pharm as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Fusion Pharm affect the company?

An increase in ROA of Fusion Pharm can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Fusion Pharm impact the company?

A reduction in the ROA of Fusion Pharm can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Fusion Pharm?

Some factors that can influence the ROA of Fusion Pharm include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Fusion Pharm important for investors?

The ROA of Fusion Pharm is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Fusion Pharm take to improve ROA?

To improve ROA, Fusion Pharm can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Fusion Pharm pay?

Over the past 12 months, Fusion Pharm paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Fusion Pharm is expected to pay a dividend of 0 USD.

What is the dividend yield of Fusion Pharm?

The current dividend yield of Fusion Pharm is .

When does Fusion Pharm pay dividends?

Fusion Pharm pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Fusion Pharm?

Fusion Pharm paid dividends every year for the past 0 years.

What is the dividend of Fusion Pharm?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Fusion Pharm located?

Fusion Pharm is assigned to the 'Non-cyclical consumption' sector.

Wann musste ich die Aktien von Fusion Pharm kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Fusion Pharm from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did Fusion Pharm pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of Fusion Pharm in the year 2023?

In the year 2023, Fusion Pharm distributed 0 USD as dividends.

In which currency does Fusion Pharm pay out the dividend?

The dividends of Fusion Pharm are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Fusion Pharm

Our stock analysis for Fusion Pharm Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fusion Pharm Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.